D.E. Shaw & Co
NTLA icon

D.E. Shaw & Co’s Intellia Therapeutics NTLA Stock Holding History

D.E. Shaw & Co’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-83,100
Closed -$747K – 4887
2025
Q4 		$747K Buy
+83,100
New +$1.14M ﹤0.01% 3718

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co's NTLA Position: Q2 2026 in Review

D.E. Shaw & Co increased its Intellia Therapeutics (NTLA) stake by 12% in Q2 2026, buying an estimated $10M and bringing the position to 6,443,323 shares worth $109M. The position accounts for 0.05% of the portfolio, ranked #418.

D.E. Shaw & Co first reported a position in NTLA in Q4 2019 and has held it in 20 quarters since. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • D.E. Shaw & Co held 6,443,323 shares of Intellia Therapeutics worth $109M as of Q2 2026.
  • D.E. Shaw & Co bought 715,146 Intellia Therapeutics shares in Q2 2026, an estimated $10M.
  • Intellia Therapeutics made up 0.05% of D.E. Shaw & Co's portfolio in Q2 2026, its #418 holding.
  • D.E. Shaw & Co first reported a position in Intellia Therapeutics in Q4 2019 and has held it in 20 quarters since.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.